在接受pioglitazone治疗的MASLD患者中改善肝纤维化:最新情况
1Department of Life Science, Health and Health Professions, Link Campus University, 00165 Roma, Italy.
Life (Basel, Switzerland)
|November 27, 2025
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 影响肝脏健康,特别是2型糖尿病. 皮奥格利塔是一种具有成本效益的治疗选择,有可能改善MASLD患者的肝纤维化,特别是在资源不足的环境中.
科学领域:
- 肝病学和内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢功能障碍相关的肥胖性肝病 (MASLD) 涵盖了从肥胖症到MASH和肝硬化的范围.
- 患有MASLD和2型糖尿病的患者面临MASH和晚期纤维化的风险增加.
- 纤维化严重程度对于长期MASLD预后至关重要,需要风险分层策略.
研究的目的:
- 审查MASLD和MASH的流行病学趋势.
- 阐明皮奥格利塔的作用机制,重点关注其抗纤维性作用.
- 总结一下MASLD治疗皮奥格利塔治疗期间纤维化评估的临床证据.
主要方法:
- 在PubMed的文献搜索中,搜索过去两年的英语研究.
- 专注于流行病学数据,皮奥格利塔的机制和临床研究.
- 在MASLD中分析皮奥格利塔对肝纤维化的影响.
主要成果:
- MASLD和MASH带来了重大的社会经济负担,特别是在低收入国家.
- 皮奥格利塔是一种 thiazolidinedione,向参与脂质代谢和炎症的 PPAR.
- 皮奥格利塔显示出作为改善MASLD肝纤维化的成本有效治疗的潜力.
结论:
- 有效的MASLD和MASH管理策略至关重要,特别是在低资源环境中具有成本效益的策略.
- 皮奥格利塔的抗纤维性质使其成为对MASLD的有希望的治疗选择.
- 需要在皮奥格利塔治疗期间对纤维化评估进行进一步的研究.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...